Influential Analyst Rating Changes: eHealth, Inc. (EHTH), Kura Oncology, Inc. (KURA)

eHealth, Inc. (NASDAQ:EHTH) tinted gains of +2.82% (+1.66 points) to US$60.61. The volume of 0.31 Million shares climbed down over an trading activity of 398.64 Million shares. EPS ratio determined by looking at last 12 month figures is -2.36. Over the same time span, the stock marked US$64.81 as its best level and the lowest price reached was US$13.61. The corporation has a market cap of US$1.19 Billion.

eHealth, Inc. (NASDAQ:EHTH)’s earnings per share has been growing at a -41.4 percent rate over the past 5 year when average revenue increase was noted as 2.1 percent. The return on equity ratio or ROE stands at -16.5 percent while most common profitability ratio return on investment (ROI) was -8.2 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of -30.1 percent and possesses 99.5 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 2.25. 6 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Kura Oncology, Inc. (NASDAQ:KURA) is worth US$550.75 Million and has recently risen 1.46% to US$14.57. The latest exchange of 0.11 Million shares is below its average trading activity of 242.27 Million shares. The day began at US$14.48 but the price moved to US$13.67 at one point during the trading and finally capitulating to a session high of US$14.61. The stock tapped a 52-week high of US$24.02 while the mean 12-month price target for the shares is US$26.71.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.15, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 84%, it carries an earnings per share ratio of -1.67.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 4 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.5.